Under the terms of the acquisition Hi-Tech receives rights to Midlothian’s current product line, consisting of prescription nutritional supplements including pre-natal vitamins and several cough and cold formulations, and future ANDA and non-ANDA products that are in development.
David Seltzer, president and CEO of Hi-Tech Pharmacal, said: “This acquisition expands Hi-Tech’s product line, broadens our dosage form offerings, brings us into new therapeutic categories, adds to the company’s growing pipeline of products and brings experienced management.”